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Abstract
Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated
for Hsp90 inhibitory activity. Replacement of the synthetically complex noviose sugar with simple
aromatic side chains produced analogs that maintain moderate cytotoxic activity against MCF7
and SkBR3 breast cancer cell-lines. Rationale for the preparation of des-noviose novobiocin
analogs in addition to their synthesis and biological evaluation are presented herein.
Heat shock protein 90 kDa (Hsp90) is a remarkably versatile molecular chaperone that plays
a key role in homeostasis.1,2 However, Hsp90 is unregulated in malignancies and facilitates
the maturation, stabilization and/or activation of more than 50 oncogenic proteins, including
several kinases and transcription factors.3–6 Thus, Hsp90 has attracted the attention of both
industrial and academic laboratories as a promising target for the development of cancer
chemotherapeutics.
Hsp90 exists as an obligate homodimer and possesses two nucleotide binding regions: 1) an
N-terminal ATP-binding pocket that manifests ATPase activity, and produces the requisite
energy for client protein maturation, and 2) a C-terminal nucleotide binding pocket that
exhibits allosteric control over substrate and co-chaperones. 2,7–10 Traditional inhibitors of
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Hsp90 disrupt the N-terminal ATP binding pocket, resulting in client protein degradation
and inhibition of cell proliferation. At present, no N-terminal Hsp90 inhibitor has been
approved by the FDA. Detriments related to N-terminal inhibition have include; induction of
the pro-survival heat shock response, as well as undesired toxicity profiles. 1,11,12 Thus, new
opportunities for Hsp90 modulation, including C-terminal inhibition, have been sought after
for Hsp90 disruption.13–21
Natural products identified as C-terminal Hsp90 inhibitors include the coumarin family of
antibiotics such as novobiocin, clorobiocin and coumermycin A1 (Figure 1).22,23 Structure-
activity relationship (SAR) studies on novobiocin, which was originally identified as a
bacterial DNA gyrase inhibitor, transformed this broad spectrum antibiotic into a potent
cytotoxic Hsp90 inhibitor.13 In addition, SAR studies revealed a class of C-terminal Hsp90
inhibitors that manifest cytotoxic activity at concentrations significantly lower than that
which is needed for induction of the heat shock response, unlike the N-terminal inhibitors in
clinical trials.24,25 Furthermore, evidence suggests that C-terminal inhibition may improve
selective client protein degradation, producing a potential improvement over N-terminal
inhibitors.24 Thus, C-terminal inhibitors of Hsp90 represent a promising option for Hsp90
modulation and may possess attributes that overcome limitations manifested with the N-
terminal inhibitors.
In pursuit of the development of more potent novobiocin analogs, we recently reported
derivatives that contain sugar surrogates in lieu of the stereochemically complex noviose
(Figure 2). These studies resulted in the attainment of compounds that exhibit nanomolar
inhibitory activity against both breast and prostate cancer cell-lines.22,25–27 In continuation
of previous optimization efforts; it was desired to replace the noviose sugar with substituted
phenyl rings via various linkages (-O, -NH and –CH2). Rationale for the design of these
analogs was three-fold: 1) Aryl ethers of novobiocin represent a novel class of
uninvestigated analogs; 2) Elimination of the stereochemically complex sugar moiety
(which requires 11-steps to prepare28), and 3) Removal of the hydrolytic sensitive glycosidic
linkage, which may limit its utility for therapeutic applications.29,30 As a result of these
studies, a non-labile and synthetically accessible class of novobiocin analogs was pursued.
Syntheses of aryl ethers 13–21 were initiated from previously reported coumarin scaffold
1,22 via the oxidative coupling with commercially available boronic acids 2–4 in the
presence of Cu(OAc)2 and pyridine to yield intermediates 5–7 in excellent yields.31,32
Removal of the carboxybenzyl (Cbz) protecting group and subsequent coupling with acid
chloride 11 or 1225–27 provided compounds 13, 15, 17 or 19–21, respectively. Finally,
hydrolysis of 13, 15 and 17 under mild conditions produced the free phenols 14, 16 and 18.
In parallel, a series of NH-linked aryl analogs 30–32 were synthesized for direct comparison
to their aryl ether counterparts. Furthermore, these analogs incorporated a hydrogen bond
donor in lieu of the ether acceptor and may therefore provide enhanced interactions with the
C-terminal binding pocket.
The NH-linked aryl analogs 30–32, were synthesized from commercially available 3-
nitro-2-methyl phenol 23, which was transformed to the corresponding amino phenol 24,
upon reduction of the nitro functionality. Intermediate 26 was afforded in reasonable yield
via a Buchwald N-arylation cross coupling33,34 of compound 24 with 4-iodo anisole 25 in
the presence of Pd(dppf)Cl2 and KOtBu in dioxane. Phenol 26 was condensed with enamine
2725–27 in acetic acid under reflux conditions to provide N-arylated coumarin 28 in
acceptable yield. Hydrogenolysis of the Cbz protecting group and subsequent coupling with
acid chlorides 11 or 12, provided analogs 30 and 32, in good yields, respectively. Finally,
methanolysis of acetate 30 yielded the corresponding phenol, 32.
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To further investigate the influence of surrogates on the activity of aryl-containing
replacements, linkers containing of a methylene in lieu of the ether or amine were also
pursued. These analogs were prepared in an effort to provide direct comparison the aryl
ethers/amines previously described. Methylene linked analogues 43–54 were prepared in 3–
5 steps commencing with the coumarin 1, which was converted to triflate 33 in the presence
of Tf2O and pyridine. Utilizing Pd-mediated borylation chemistry,35 intermediate 34 was
obtained in one-step. Interestingly, the vinylogous amide was deprotected simultaneously
under the enlisted conditions, which was required for benzamide formation. Subsequent
coupling of amine 34 with acid chloride 11 or 12 provided analogs 35 and 36 respectively,
in excellent yield.
Finally, palladium-catalyzed Sp2-Sp3 coupling36–38 of 35 with benzyl bromides 37–42 in the
presence of K2CO3 yielded compounds 43, 45, 47, 49 and 51, respectively, in respectable
yields. Methanolysis of aryl acetates 43, 45, and 47 yielded compounds 44, 46 and 48,
respectively. In addition, analogs 50 and 52 were produced via acid mediated hydrolysis of
the acetate and MOM groups present in 49 and 51 in single step. Intermediate 36 was also
coupled with benzyl bromides 37 and 38 to yield compounds 53 and 54, respectively.
Upon preparation of these non-hydrolysable novobiocin analogs with various linkers (-O, -
NH and -CH2), the compounds were evaluated for anti-proliferative activity against SkBR3
and MCF7 breast cancer cell-lines. In general, the ether analogs containing a prenylated aryl
side chain (13–18) maintained moderate efficacy, whereas compounds exhibiting the biaryl
side chain (19–21) displayed IC50 values >100 μM. This observation is noteworthy, as the
presence of the prenylated functionality in noviosylated novobiocin analogs attenuates the
antiproliferative activity, suggesting that simple replacement of the sugar moiety with an
aryl appendage significantly alters the mode of binding. Furthermore, analysis of analogs
13–18 suggests a cell-line sensitivity to the appended methyl ether. The 3′-OMe analogs (15
and 16) were slightly more active than the corresponding 4′-OMe analogs (13 and 14)
against SKBr3 cell lines; however, 13 and 14 were more active against MCF-7 cell lines.
The aryl ether analogs also indicate that steric bulk at the 4′-position attenuates activity, as
all aryl ethers containing a 4′t-BuOH moiety (17, 18, and 21) exhibited inferior anti-
proliferative activities, suggesting spacial limitations at this region of the binding pocket.
Methylene linked analogs, 43, 44, 46 and 48–54, were also evaluated for anti-proliferative
activity. With the exception of 54 and 48, methylene linked compounds exhibited a
relatively flat SAR, manifesting equipotency against both MCF-7 and SkBR3 cell lines.
Compound 48, exhibits moderate activity (~13 μM) against MCF-7 cells, but is inactive up
to 100 μM against SkBR3 cells. Although, novobiocin-based analogs are typically slightly
more active against MCF-7 cells, the ~10-fold sensitivity to 48 is intriguing. Compound 53
represents the most active aryl linked compound identified in this series, and manifested
IC50 values of ~4 μM and ~7 μM against SkBR3 and MCF-7 cancer cells, respectively.
Surprisingly, the NH-linked analogs exhibit no anti-proliferative activity against MCF-7 or
SkBR3 cell lines up to 100 μM, suggesting that replacement of the ether linker with an NH
moiety precludes binding. This result suggests that a hydrogen bond donor at this location
and/or the conformational induced via the NH linker may be detrimental to binding and
novobiocin analogs containing such features should not be pursed.
In order to confirm inhibition of Hsp90, two representative compounds, 14 and 43, were
evaluated for their ability to induce Hsp90 client protein degradation. As expected for a C-
terminal Hsp90 inhibitor, client protein degradation was observed and indicative of C-
terminal inhibition, no Hsp90 induction was seen. This is in contrast to N-terminal Hsp90
inhibitors, which induce the heat shock response at the same concentration needed to induce
client protein degradation.
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In conclusion, a series of non-hydrolyzable novobiocin analogs that contain non-
hydrolysable linkers (-O, -NH and –CH2) was designed, synthesized and evaluated for
Hsp90 inhibitory activity against SkBR3 and MCF7 breast cancer cell-lines. Replacement of
the synthetically complex noviose sugar with simple ether or methylene linked aromatic side
chains resulted in moderate anti-proliferative activity that is attributable to Hsp90 C-terminal
inhibition. These non-hydrolyzable novobiocin analogs provide a class of C-terminal Hsp90
inhibitors that can be obtained through an expedient process, as the synthetically complex
noviose has been eliminated.
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Representative Natural Product Hsp90 C-terminal inhibitors.
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Western blot analyses of Hsp90 client protein degradation assays against MCF-7 cells.
Concentrations (in μM) of 14 (top) and 43 (bottom) are indicated above each lane. GDA
(geldanamycin, 500 nM) and DMSO were respectively employed as positive and negative
controls.
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Synthesis of O-linked non-labile novobiocin analogs.
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Synthesis of N-linked non-labile novobiocin analogs.
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Synthesis of methylene linked novobiocin analogs.
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